Market leadership Oncotech is a specialized molecular oncology testing provider with a preeminent position in in vitro drug resistance and therapy selection testing, serving over a thousand hospitals in the US and Europe. This suggests sales opportunities with large hospital networks and cancer centers seeking advanced diagnostic capabilities.

Growth potential Revenue is in the $10M–$25M range with a lean employee base, indicating room for expansion through additional hospital contracts, expanded service lines, or higher-margin genomic research collaborations as they scale.

Acquisition heritage Historically backed by Qiagen via Exiqon, Oncotech benefits from a lineage of established partnerships and credibility in oncology diagnostics, which can be leveraged to open dialogues with prospective customers and strategic investors seeking validated clinical impact.

Expansion targets Given current hospital-based service delivery across the US and Europe, there are opportunities to upsell to larger multi-site health systems, negotiate enterprise licensing, and offer integrated genomic research collaborations to accelerate diagnostic discovery.

Tech-enabled trust The tech stack emphasizes robust web and security foundations (Windows Server, ASP.NET, IIS, HSTS, XSS protection, GlobalSign), which can be highlighted when engaging IT leaders for audits, data protection assurances, and compliant reporting in oncology diagnostics.